New, less-expensive inactivated polio vaccine non-inferior to conventional inactivated vaccine

2019 ◽  
Vol 212 ◽  
pp. 241-242
Author(s):  
Andrew Kreppel
2015 ◽  
Vol 49 (0) ◽  
Author(s):  
Ana Marli Christovam Sartori ◽  
Margarete Paganotti Vicentine ◽  
Lígia Castelloni Figueiredo Gryninger ◽  
Patricia Coelho de Soárez ◽  
Hillegonda Maria Dutilh Novaes

OBJECTIVE To analyze the costs of vaccination regimens for introducing inactivated polio vaccine in routine immunization in Brazil.METHODS A cost analysis was conducted for vaccines in five vaccination regimens, including inactivated polio vaccine, compared with the oral polio vaccine-only regimen. The costs of the vaccines were estimated for routine use and for the “National Immunization Days”, during when the oral polio vaccine is administered to children aged less than five years, independent of their vaccine status, and the strategic stock of inactivated polio vaccine. The presented estimated costs are of 2011.RESULTS The annual costs of the oral vaccine-only program (routine and two National Immunization Days) were estimated at US$19,873,170. The incremental costs of inclusion of the inactivated vaccine depended on the number of vaccine doses, presentation of the vaccine (bottles with single dose or ten doses), and number of “National Immunization Days” carried out. The cost of the regimen adopted with two doses of inactivated vaccine followed by three doses of oral vaccine and one “National Immunization Day” was estimated at US$29,653,539. The concomitant replacement of the DTPw/Hib and HepB vaccines with the pentavalent vaccine enabled the introduction of the inactivated polio without increasing the number of injections or number of visits needed to complete the vaccination.CONCLUSIONS The introduction of the inactivated vaccine increased the annual costs of the polio vaccines by 49.2% compared with the oral vaccine-only regimen. This increase represented 1.13% of the expenditure of the National Immunization Program on the purchase of vaccines in 2011.


The Lancet ◽  
2020 ◽  
Vol 395 (10230) ◽  
pp. 1163-1166
Author(s):  
Jorge A Alfaro-Murillo ◽  
Marí L Ávila-Agüero ◽  
Meagan C Fitzpatrick ◽  
Caroline J Crystal ◽  
Luiza-Helena Falleiros-Arlant ◽  
...  

2014 ◽  
Vol 31 (10) ◽  
pp. 2618-2629 ◽  
Author(s):  
Heleen Kraan ◽  
Paul van Herpen ◽  
Gideon Kersten ◽  
Jean-Pierre Amorij

2011 ◽  
Vol 18 (8) ◽  
pp. 1387-1390 ◽  
Author(s):  
Diana Kouiavskaia ◽  
Marc S. Collett ◽  
Eugenia M. Dragunsky ◽  
Andrey Sarafanov ◽  
Konstantin M. Chumakov

ABSTRACTImmunization of mice with inactivated polio vaccine (IPV) with concurrent dosing of poliovirus antiviral V-073 showed no detrimental impact on the elicitation of serum-neutralizing antibodies. A strategy involving coadministration of antiviral V-073 and IPV can be considered for the management of poliovirus incidents.


2015 ◽  
Vol 11 (12) ◽  
pp. e1005316 ◽  
Author(s):  
Sarah Knowlson ◽  
John Burlison ◽  
Elaine Giles ◽  
Helen Fox ◽  
Andrew J. Macadam ◽  
...  

2018 ◽  
Vol 67 (suppl_1) ◽  
pp. S57-S65 ◽  
Author(s):  
James T Gaensbauer ◽  
Chris Gast ◽  
Ananda S Bandyopadhyay ◽  
Miguel O’Ryan ◽  
Xavier Saez-Llorens ◽  
...  

Vaccine ◽  
2020 ◽  
Vol 38 (21) ◽  
pp. 3780-3789
Author(s):  
Xavier Sáez-Llorens ◽  
Birgit Thierry-Carstensen ◽  
Lina Saem Stoey ◽  
Charlotte Sørensen ◽  
Henrik Wachmann ◽  
...  

2020 ◽  
Vol 35 (Supplement_1) ◽  
pp. i30-i37
Author(s):  
Mirembe Rachel Faith ◽  
Babirye Juliet ◽  
Nathan Tumuhamye ◽  
Tumwebaze Mathias ◽  
Emma Sacks

Abstract Uganda officially introduced the inactivated polio vaccine (IPV) in May 2016 as part of the polio eradication strategy and integrated it into its routine immunization programme in addition to the oral polio vaccine. The current coverage stands at 60% as of July 2017. We therefore aimed to determine factors associated with the uptake of IPV among children in Kalungu District so as to inform the implementation of the vaccine policy. A community-based cross-sectional study was conducted among caregivers of 406 eligible children aged 12–23 months through multi-stage systematic sampling and a standardized semi-structured questionnaire. Nine key informant interviews were conducted through purposive selection of health care providers and members of Village Health Teams (VHTs) based on their expertize. Modified Poisson regression and thematic content analysis were used to determine factors significant to IPV uptake among children. 71% of sampled children aged 12–23 months had received IPV in Kalungu District. The survey found that being encouraged by health workers and VHTs was significant to children’s uptake of IPV (Adjusted PR 1.24, 95% CI; 1.22–3.47). Distance to the immunization point (Adjusted PR 0.32,95% CI; 0.16–0.62) and caregiver’s education level (Adjusted PR 1.16,95% CI; 1.05–2.22) were also associated with IPV uptake. Qualitative findings from health workers and VHT members further confirmed the perception that distance to the immunization post was important, and VHTs also stated that being encouraged by health workers was critical to IPV uptake. The current prevalence of IPV uptake among children aged 12–23 months in Kalungu is 71%, higher than the last reported national coverage (60%), though still below the recommended national coverage of 95%. Efforts should be focused on sensitization of caregivers through health workers and VHTs. Immunization outreach should be strengthened so as to bring services closer to patients.


Sign in / Sign up

Export Citation Format

Share Document